The company develops various products including Altat, a H2 blocker for the treatment of digestive ulcers and gastritis; and Prostal, a drug for the treatment of benign prostatic hypertrophy and prostate cancer. ASKA partners with other Japanese and overseas companies to develop drugs such as BNP7787, an antineoplastic effect enhancer for antineoplastic drugs, and AKP-501, an infertility medication which contains genetically modified follicle-stimulating hormone(r-FSH). ASKA's drugs are used in the treatment of digestive ulcers, hypothyroidism, gastritis, benign prostatic hypertrophy and prostate cancer. The company categorized its business activities into: research and development, production and drug information activities. ASKA is headquartered in Minato-ku, Tokyo, Japan. This comprehensive SWOT profile of ASKA Pharmaceutical Co., Ltd. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of ASKA Pharmaceutical Co., Ltd. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends). The profile contains critical company information including*, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. For more information kindly visit : http://www.companyprofilesandconferences.com/researchindex/Pharmaceuticals-Healthcare-c13/ASKA-Pharmaceutical-Co-Ltd-4514-Financial-and-Strategic-SWOT-Analysis-Review2.html Or Contact us at : Company Profiles And Conferences Mob +919223375060 / 919223767111 Fax : +91 22 27810778 E-mail : info@companyprofilesandconferences.com Website : www.companyprofilesandconferences.com
Related Articles -
PharmaceuticalS, healthcare, market reseaech.,
|